Head and Neck Cancer Cancer Oncology Immunotherapy
| A promising new study released by the University of Colorado Cancer Center suggests that recurrence of certain cancers can be significantly decreased by irradiating only a select set of lymph nodes near a tumor rather than all of them. |
Laura Kelley | 
November 16, 2022
Ovarian Cancer Immunotherapy Genetics
People often tell Winona Williams that she’s brave, and she is. Ovarian cancer could easily become a dark cloud over her, shadowing every minute of every day.
Rachel Sauer | September 20, 2022
Research Immunotherapy lymphoma
Large B-cell lymphoma (LBCL) is one of the most aggressive lymphomas and accounts for about 30% of all lymphoma diagnoses.
Rachel Sauer | July 14, 2022
Research Lung Cancer Immunotherapy
An exciting and innovative area of cancer research is immunoprevention, in which studies focus on preventing cancer before its onset by using vaccines, antibodies, and other immune mechanisms.
Rachel Sauer | July 06, 2022
Patient Care Lung Cancer Prostate Cancer Melanoma Immunotherapy
To understand why Beau Gill built a mental cupboard for Jeff and Spike, first you must travel back with him to the small town of Catemaco in Mexico’s state of Veracruz.
Rachel Sauer | April 20, 2022
Immunotherapies have revolutionized the care of many cancers, teaching the body’s own immune cells to recognize and attack tumor cells. Leading the way are drugs known as checkpoint inhibitors, which block a kind of “white flag” that tumors wave as a peace signal to T cells that would very much like to kill them. Really, this white flag is a protein called PD-L1 – many tumors coat themselves in it. When PD-L1 on the surface of a cancer cell sees its partner, PD1, on T cells, these T cells are tricked into letting the cancer cell live. To counteract this dirty trick, checkpoint inhibitor drugs block the functions of PD-L1 on tumor cells (e.g. atezolizumab) or PD1 on T cells (e.g. pembrolizumab), allowing T cells to go about their cancer-killing business.
Cancer Center | June 24, 2019
Melanomas tend to be “hot” or “cold” – if they’re hot, immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50 percent of melanomas are cold, making them invisible to the immune system, and patients with cold tumors tend to show little benefit from immunotherapies. The problem is that it’s been impossible to distinguish a hot melanoma from a cold one – the solution has been to administer immunotherapy and hope for the best, often leading to wasted time and resources. Now a University of Colorado Cancer Center study presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 identifies a possible way to predict which melanomas are hot and cold: Tumors with mutations in genes leading to over-activation of the NF-kB signaling pathway were more than three times as likely to respond to anti-PD1 immunotherapy compared with tumors in which these changes were absent.
Cancer Center | April 02, 2019
Targeted Oncology
November 16, 2022
During a roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.
Cancer Health
November 15, 2022
November is Pancreatic Cancer Awareness Month. Laura Foote shares her story to bring hope and express gratitude.
TIME
November 15, 2022
Men are three to four times more likely than women to develop bladder cancer, but the disease tends to be deadlier in females. Why?
Biospace
November 14, 2022
New therapeutic addresses need in patients suffering with cold and refractory tumors.
